Eisai US’ Post

Interesting article from Medscape on exciting new research developments in the diagnostic testing approach for Amyotrophic Lateral Sclerosis (ALS). A new blood-test, used in addition to clinical evaluation may help speed up time to confirmed diagnosis. "Blood-based diagnostic biomarkers for ALS are essential for reducing diagnostic delays and improving disease outcomes." The test's ability to accurately distinguish ALS in patients would help "enhance diagnostic confidence", leading to timely interventions and improved quality of life for those affected. #HealthcareInnovation https://hubs.ly/Q02Q5L0b0

Surprising yet true - nearly 25% of cancers are considered 'rare'. These uncommon cancers and tumors are often elusive, posing unique challenges to medical science. In the biopharma world, we are harnessing innovation and cutting-edge technology to provide solutions, one rare disease at a time. Join us in shedding light on these under-researched fields, bringing hope to those affected by these elusive diseases. #RareDiseases #CancerResearch #BiotechPharma #InnovativeHealthcare #FightingRareCancer

Cogstate Chief Innovation Officer, Prof Paul Maruff, shared data at the recent ADPD meeting showcasing the association between performance on Cogstate tests and biomarkers of Alzheimer’s disease. “These relationships were strong and statistically significant,” said Maruff. “They provide for us now a basis to start to understand the absolute genesis of Alzheimer’s disease, when it begins, and how it manifests.” 📊 View the poster here: https://lnkd.in/edYxJ7hN 🎥 Watch the poster video summary here: https://lnkd.in/ePtPQXjc

The provision of cancer care requires an holistic approach. Crucial to this, lies nutritional support. This upcoming webinar will yield new perspectives to improve clinical outcomes in oncological care. Kudos to Saspen 👏.

#ICYMI: a clinical paper was published in the Annals of Intensive Care which shows that our Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis. Click to read the paper: tinyurl.com/4tn3skje

#ACROHighlights [Featured Product] 🔬 Discover the Potential of TL1A/DR3 Pathway in Autoimmune Disease Treatment! The TL1A/DR3 pathway plays a key role in regulating inflammation and its dysregulation has been implicated in many autoimmune diseases. We offer a range of TL1A and DR3 proteins and a TL1A-stable cell line to support your research into developing novel therapies targeting this pathway. Explore various species, tags, and labels to customize your experiments. Don't miss out on this exciting avenue for advancing your autoimmune disease research! 💡 👉 Check out our TL1A/DR3 products here: https://smpl.is/8wgn0 #AutoimmuneDiseaseResearch #TL1A #DR3Pathway #BiotechSolutions

On this World Lung Day, we would like to emphasize the importance of Krebs von den Lungen-6 (#KL-6) as a key biomarker for interstitial pneumonia. KL-6, a high molecular weight glycoprotein, is a reliable serum biomarker for interstitial lung diseases (ILD). It plays a key role in diagnosis, monitoring disease activity, evaluating treatment response, and predicting clinical outcomes. Due to the complexity of ILD, patients are frequently misdiagnosed, which could lead to delays in appropriate management #WorldLungDay #Lung #laboratory #laboratoryequipment #diagnosis

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and UCL, gives you his update in this MEDtalk. #Alzheimers 

2023 was a big year for us to celebrate as we accomplished multiple firsts in the global fight against Alzheimer’s disease. Among these milestones, our Precivity™-related biomarkers appeared in multiple global phase 3 clinical efficacy studies to help demonstrate biological activity of anti-amyloid therapies. In August, we launched the PrecivityAD2™ blood test in the U.S., a unique innovation with high concordance to Amyloid PET and CSF that’s helping to transform clinical care for individuals with cognitive impairment. Then, on World Alzheimer’s Day, we expanded its reach to #Brazil. A partnership with Grupo Fleury is helping Brazilians receive accurate and early Alzheimer’s disease diagnoses.   https://lnkd.in/ekPAmH5g   #yearinreview #Brazil #diagnosis #alzheimersdisease

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and University College London, gives you his update in this MEDtalk. #Alzheimers